Fascial Therapy in Elbow Hemophilic Arthropathy (HeL-Fascial)
Hemophilia
About this trial
This is an interventional treatment trial for Hemophilia focused on measuring Hemophilia, Elbow, Arthropathy, Joint pain, Range of motion, Myofascial techniques, Safety patients, Quality of life, Functionality
Eligibility Criteria
Inclusion Criteria:
- Patients diagnosed with hemophilia A and B
- Patients adults (over 18 years)
- Patients diagnosed with hemophilic arthropathy of the elbow (by clinical assessment with the Hemophilia Joint Health Score)
- Patients pn prophylactic treatment with FVIII / FIX concentrates.
Exclusion Criteria:
- Patients without ambulation ability
- Patients with inhibitors
- Patients with neurological or cognitive alterations that impede the comprehension of the questionnaires and physical tests
- Patients who have not signed the informed consent document.
Sites / Locations
- Royal Victoria Eugenia Foundation
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Expermiental group
Control group
All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.